Eisai Adopts Elix Discovery Platform to Accelerate AI-Driven Drug Development
Eisai has adopted Elix Discovery™, an AI drug discovery platform developed by Tokyo-based Elix, to accelerate innovation in its drug development pipeline.3
Elix Discovery™ leverages federated learning, enabling AI models to be trained on confidential datasets from 16 major Japanese pharmaceutical companies without sharing proprietary data, thus preserving confidentiality while creating advanced predictive and generative models for drug discovery tasks.15
The models were trained with over 1 million compounds and 10 million data points contributed by consortia members, mainly participants in the AMED-backed DAIIA initiative, which ran from 2020 to 2025 and included leading institutions like RIKEN and Kyoto University.15
This marks the world's first commercial deployment of an AI drug discovery platform at this scale using federated learning in the pharmaceutical sector.15
Eisai expects that integrating Elix Discovery™ will boost the capabilities of its medicinal chemists and enhance the AI-powered molecular design process, with the aim of creating innovative new medicines.3
Sources:
1. https://www.biopharmatrend.com/post/1315-japans-elix-launches-ai-drug-discovery-platform-trained-on-confidential-pharma-data-via-federated-learning/
3. https://www.businesswire.com/news/home/20250715531249/en/Elix-Provides-AI-Drug-Discovery-Platform-Elix-Discovery-to-Eisai
5. https://www.businesswire.com/news/home/20250711005829/en/Elix-and-LINC-Become-the-First-in-the-World-to-Commercialize-an-AI-Drug-Discovery-Platform-Incorporating-Federated-Learning-Based-AI-Models-Trained-on-Data-from-16-Pharmaceutical-Companies